AI Medical Device Company Aillis Selected for Tokyo's "SusHi Tech Global" Growth Acceleration Program Phase 1

Aillis Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Sho Okiyama; hereinafter referred to as "the Company") is pleased to announce that it has been selected as a supported company for the first phase of the "SusHi Tech Global" Growth Acceleration Program implemented by the Tokyo Metropolitan Government. We will utilize the financial support and accompanying assistance provided through this program to accelerate the global expansion of our AI medical devices, which we develop and provide.

■ About the "SusHi Tech Global" Growth Acceleration Program

In its startup strategy "Global Innovation Strategy 2.0 STARTUP & SCALEUP," the Tokyo Metropolitan Government positions "global" x "scale-up" as a new pillar of its initiatives and is promoting the "SusHi Tech Global" project, which intensively supports companies aiming for dramatic global growth. This time, as the first phase of the "Growth Acceleration Program," which selects startups that can expect rapid "scale-up" by promoting global expansion at this timing within SusHi Tech Global, 10 companies including ours have been selected. Selected companies will receive financial support of up to 200 million yen over a maximum of 18 months, as well as tailor-made accompanying support covering everything from business strategy formulation to overseas travel, in addition to specialized knowledge and specialized support utilizing a global network, including in the AI and healthcare fields.

To date, the Company has been working to digitize pharyngeal examinations and create new medical value through data utilization, through the development and dissemination of AI medical devices. By utilizing the support from this program and the global network of diverse experts, we will accelerate the overseas expansion of Japan-originated medical AI technology. Moving forward, the Company will continue to promote the social implementation of AI medical devices, respond to changing medical needs worldwide, and aim to build a sustainable medical infrastructure across borders.

■ About Aillis

Founded in 2017 with the mission of "creating open healthcare that everyone can co-create." A large number of professionals, including Representative Okiyama, who is a practicing physician, medical professionals, former government officials from the Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry, data scientists specializing in AI medical fields, and former employees of major medical device manufacturers, are gathered here to develop AI medical devices that digitize the skilled techniques of doctors using deep learning technology (AI technology).

【Company Profile】

・Company Name: Aillis Co., Ltd.

・Representative Director: Sho Okiyama

・Business Activities: Development, manufacturing, and sales of AI-powered medical devices, and research and development of machine learning technology

・Established: November 2017

・Headquarters: 28-4 Kanda Higashimatsushita-cho, Chiyoda-ku, Tokyo 101-0042

・Company URL: https://aillis.jp/